Omeros to start Phase III trial of OMS721 to treat IgA nephropathy

Omeros Corp. (NASDAQ:OMER) said it reached an agreement with FDA on the design of a Phase III trial to test OMS721 in patients with IgA nephropathy. The company expects

Read the full 295 word article

How to gain access

Continue reading with a
two-week free trial.